Aims-To analyse the distribution of OV-TL 3 and MOv18 in normal ovarian tissue to determine which antibody is most suitable for (radio)immunotherapy of ovarian carcinoma. Methods-The distribution of OV-TL 3 and MOvl8 was determined using immunohistochemistry and flow cytometry.
scintigraphy and immunotherapy. OV-TL 3 and MOv18 are both directed against antigens highly expressed on ovarian carcinoma cells. ' by OV-TL 3, OA3, was identified as a novel multimembrane spanning protein, 10 whereas the antigen recognised by MOv18 is a membrane associated, folate binding protein (FBP) . 1112 In monoclonal antibody based immunotherapy in which the antibody is used alone, or conjugated to toxins, drugs or radionuclides, the reactivity with normal tissues has to be limited to avoid non-specific targeting of normal tissues. Staining with OV-TL 3 was reported to be negative in normal tissues, except for weak and irregular reactivity in some ovarian cysts and in epithelial cells lining the female genital tract.' Normal bone marrow and blood cells were not studied. In the initial report MOv18 showed no reactivity with normal tissues,2 but Stein et al reported reactivity with the epithelium of renal tubules, pancreas, lung, salivary glands, Fallopian tubes, and endocervix. 13 In the present study we have analysed the normal tissue distribution of OV-TL 3, m-MOvl 8 and c-MOv1 8 more extensively to select the most appropriate antibody for (radio)immunotherapy of ovarian carcinoma. Primary tumours and metastases of 46 patients with ovarian carcinoma were also examined using immunohistochemistry. OV-TL 3 reacted strongly (+ +) with the white cortex of the brain and moderately (+) with the perineurium of peripheral nerves. Moderate reactivity was also observed with the endothelial cells and the epithelium of sebaceous glands in the skin. The ciliated epithelium of the bronchi were moderately stained, whereas the pneumocytes were negative. In the intestine both the goblet cells and the plexus located in the submucosa of the intestine and between the longitudinal and inner circular muscle layers were stained positively (fig 1) . Positive staining was also observed in the glomeruli of the kidney and transitional cells of the bladder. A positive reaction was also observed in epithelial cells of the normal ovary, the Fallopian tubes, the endometrium, and the cervix. Placental trophoblasts also stained positively. Weak reactivity was observed in some other tissues (table 1) . On staining with OV-TL 3, a positive reaction 1) . The follicular epithelium of the ovary, the epithelial lining of the Fallopian tubes, and the placental trophoblasts also stained positively. Weak reactivity (±) was evident in some other tissues. In the thymus 10-20% of stromal cells stained weakly, whereas lymphocytes and Hassall bodies were negative ( OC 125 reacted with 41 (89%) of the 46 ovarian carcinomas tested. Staining intensity was strong in 31, moderate in eight and weak in two. Tumours samples from five patients were completely negative, two of whom had recurrent disease diagnosed as poorly differentiated serous ovarian carcinomas, while the remaining three had primary disease diagnosed as well differentiated endometroid, moderately differentiated mucinous and poorly differentiated serous ovarian carcinoma, respectively. The reaction pattern of an ovarian carcinoma tissue section on staining with OV-TL 3, MOv18 and OC 125 is shown in fig 2. Discussion In the present study normal and ovarian carcinoma tissues were analysed for their reactivity with OV-TL 3, m-MOvl8 and c-MOv18. OV-TL 3 was previously reported by Poels et al to be non-reactive with skin, stomach, prostate, kidney, colon, liver, spleen, lung, and mesothelium.1 Weak staining was found in the epithelial lining of the female genital tract such as the endocervix, endometrial glands, Fallopian tubes, and in some ovarian cysts. Our study confirms the reported reactivity in the female genital tract. We also observed reactivity in bronchial epithelium, endothelial and epithelial cells in the skin, goblet cells and ganglion cells in the intestine, ductal and acinar cells in salivary gland and pancreas, Langerhans' cells, Kupffer cells, glomeruli in kidney, transitional cells in the bladder, epithelial cells in breast, placenta, and prostate, brain cells, and peripheral nerves. The discrepancies might be explained by methodological differences. Poels et al used an indirect immunofluorescence assay, with possible fluctuations in specificity. Furthermore, background staining observed with OV-TL 3 might have obscured specific staining in normal tissues. Radiolabelled OV-TL 3 and MOvl8 have been used for radioimmunotargeting in patients with ovarian carcinoma.346 9 The radiolabelled antibodies localised preferentially in ovarian cancer lesions, as shown by the positive immunoscintigrams and high uptake of radioactivity in tumour tissue compared with uptake in normal tissues, such as skin, muscle, fat, and normal peritoneum. Uptake in normal tissues observed on immunoscintigrams was as expected. No changes in haematological or chemnical profiles were observed after injection of radiolabelled OV-TL 3 F(ab')2 or c-MOvI8.69 OV-TL 3 was reported to be more useful for immunolocalisation compared with OC 125 because it is more homogeneously distributed within ovarian cancer tissue, the antigen is not shed, and is more favourably distributed in tumour bearing, athymic mice.2326
In the present study OV-TL 3, MOv18 and CA 125 reacted with 100%, 98%, and 89% of the carcinomas examined, respectively. For each monoclonal antibody, the sensitivity was higher for serous ovarian carcinomas than with other types. Both findings agree with observations in other studies.' 151627 Heterogeneous staining intensity was observed within different peritoneal metastases of the same patient with all three monoclonal antibodies.
In antibody based immunotherapy, uptake of the monoclonal antibody in normal tissues might be detrimental when a high dose of antibody is required. However, it is unlikely that low level expression of an antigen in normal tissues will elicit side effects if the antibody directed against this antigen is applied clinically. 28 
